Physician profile
Oday Saeed
NPI 1639432164
$3,116.82
in general payments reported to CMS, 2019-2025
22 companies · $186 in 2025
The $186 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $388 · 2020: $192 · 2021: $948 · 2022: $861 · 2023: $151 · 2024: $391 · 2025: $186.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $707 · Education: $20.93.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $707.25 |
| Education | $20.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $798.05 | 2021-2025 | |
| Vifor Pharma, INC. | $334.45 | 2019-2025 | Veltassa |
| Astrazeneca Pharmaceuticals LP | $324.53 | 2021-2024 | Andexxa, Lokelma |
| Fresenius USA Marketing, INC. | $291.21 | 2019-2024 | Velphoro |
| Opko Pharmaceuticals, LLC | $250.59 | 2019-2022 | |
| Aurinia Pharma U.S., INC. | $217.55 | 2021-2022 | |
| Amgen INC. | $198.30 | 2019-2022 | |
| Mallinckrodt Enterprises LLC | $172.16 | 2019 | |
| Horizon Therapeutics Plc | $103.58 | 2023 | Krystexxa |
| Glaxosmithkline, LLC. | $59.76 | 2021-2022 | |
| Amarin Pharma, INC. | $58.92 | 2019-2020 | |
| Akebia Therapeutics INC | $57.55 | 2019-2021 | |
| Calliditas Therapeutics US INC. | $47.88 | 2022 | |
| Veloxis Pharmaceuticals, INC. | $45.46 | 2022 | |
| Nxstage Medical, INC. | $33.49 | 2024 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $21.06 | 2025 | |
| Travere Therapeutics, INC. | $20.93 | 2024-2025 | Filspari |
| Lexicon Pharmaceuticals, INC. | $17.83 | 2024 | |
| Ultragenyx Pharmaceutical INC. | $16.54 | 2021 | |
| Daiichi Sankyo INC. | $16.21 | 2021 | |
| Alnylam Pharmaceuticals INC. | $15.40 | 2019 | |
| Novo Nordisk INC | $15.37 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Oday Saeed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.